At the Annual General Meeting 2020 a
revised Remuneration Policy was adopted by the shareholders. The
informationt below will be updated to reflect the new policy as soon
In connection to the Annual Report Novo Nordisk prepares a Remuneration Report that describes the remuneration awarded or due during the previous financial year to the members of the Board and the Executive Management of Novo Nordisk A/S as registered with the Danish Business Authority.
The Remuneration Report 2019 also includes a description of key developments in remuneration in the financial year, the actual remuneration of board members and executives, an overview of remuneration awarded during the previous five financial years, remuneration benchmarks and shareholdings by board members and executives. The Remuneration Report 2019 is inspired by section 139b of the Danish Companies Act and in accordance with the Recommendations on Corporate Governance issued in November 2017 by the Danish Committee on Corporate Governance.
The Board regularly reviews board fees based on recommendations from the Remuneration Committee. When preparing its recommendation, the Remuneration Committee will be guided by comparable information from Danish and other Nordic companies as well as European pharmaceutical companies, which in size, complexity and market capitalisation are similar to Novo Nordisk. The results of the annual remuneration benchmark are presented to the Board at its October meeting.
At the December meeting the Board agrees on recommendations for
remuneration levels for the next financial year. In connection with
the approval of the annual report in January, the Board approves the
recommendation for actual remuneration for the past financial year and
endorses the recommendation on remuneration levels for the current
financial year. This is then presented to the Annual General Meeting
for approval as separate agenda items.
Each board member receives a fixed base fee per year. Ordinary board members receive a fixed amount (the base fee) while the Chairmanship receives a multiplier thereof.
Service on the Audit Committee, the Nomination Committee, the Remuneration Committee and the Research & Development Committee also entitles members to receive a multiplier of the fixed base fee in addition to their board membership fee. The remuneration composition for the members of the Board of Directors is illustrated in the table below.
Individual board members may take on specific ad hoc tasks outside the normal duties assigned by the Board. In such cases the Board determines a fixed fee for the work.
The remuneration level for 2020 as approved by the Annual General
Meeting in March 2020 is illustrated in the table below.
In addition to the fixed fee, Novo Nordisk pays such contribution to social security taxed within EU imposed by foreign authorities in relation to the fixed fee.
All board members are paid a fixed travel allowance per board meeting and per committee related meeting. No travel allowance is paid to board members when no travel is required to attend board meetings or committee related meetings.
The travel allowances for 2020 as approved by the Annual General
Meeting in March 2020 are illustrated in the table below.
Expenses, such as travel and accommodation in relation to board meetings as well as relevant education, are reimbursed.
Board members are not offered stock options, warrants or participation in other incentive schemes.
Executive remuneration is proposed by the Remuneration Committee and
subsequently approved by the Board. Levels are evaluated annually
against a benchmark of relevant Danish and Nordic companies as well as
European pharmaceutical companies, which in size, complexity and
market capitalisation are similar to Novo Nordisk. To ensure
comparability, executive positions are evaluated in accordance with an
international position evaluation system which, among other
parameters, includes and reflects the development of the company size
measured in terms of company revenue and number of employees.
Executive and board remuneration benchmark surveys are fully
The remuneration package consists of a fixed base salary, a cash-based incentive, a long-term share-based incentive, a pension contribution and other benefits. For executives on international assignment at the request of the company, the remuneration package is generally based on an equalized host country net salary during the length of the assignment.
The short-term incentive programme may result in a maximum payout per year equal to 12 months’ fixed base salary plus pension contribution. The long-term incentive programme may result in a maximum share allocation per year equal to 24 months' fixed base salary plus pension contribution. Consequently, the aggregate maximum amount that may be granted as incentives for a given year is equal to 36 months' base salary plus pension contribution. The split between fixed and variable remuneration is intended to result in a reasonable part of the salary being linked to performance, while promoting sound long-term business decisions to achieve the company’s objectives.
The fixed base salary is intended to attract and retain executives with the professional and personal competences required to drive the company’s performance.
The short-term incentive programme is designed to incentivise the individual executive for individual performance within his/her functional area and to ensure short-term achievements in line with company needs. It may result in a maximum payout per year equal to 12 months’ fixed base salary plus pension contribution. The Board of Directors determines at the beginning of each year the maximum short-term incentive programme for each participating member for the given year.
Short-term targets for the chief executive officer are fixed by the chair of the Board, while the targets for the other members of Executive Management are fixed by the chief executive officer. The Chairmanship evaluates the degree of achievement for each member of Executive Management based on input from the chief executive officer.
Short-term incentives are subject to recovery or "claw-back" by Novo Nordisk, provided the remuneration was paid on the basis of data which proved to be manifestly misstated. Claw-back in relation to the short-term incentives is possible up to 12 months after the actual payment of the cash-based incentive.
The long-term incentive programme is designed to promote the collective performance of Executive Management and align the interests of executives and shareholders. It further ensures a balance between short-term achievements and long-term thinking. It may result in a maximum payout per year equal to 24 months' fixed base salary plus pension contribution.
Each year in January the Board decides whether to establish a long-term incentive programme for that calendar year. The long-term incentive programme is based on the degree of achievement of the planned economic value creation and on the degree of achievement of the planned level of sales growth.
Aligned with Novo Nordisk's long-term financial targets, the calculation of economic value creation is based on reported operating profit after tax reduced by a weighted average cost of capital (WACC)-based return requirement on average invested capital. For executives the LTIP operates with a yearly maximum share allocation per executive equal to 18 months' fixed base salary plus pension contribution for the chief executive officer and 13.5 months’ fixed base salary plus pension contribution for the executive vice presidents. The Board of directors determines at the beginning of each year the maximum allocation per participant for the given year.
Further, the Board of Director identifies a number of significant research and development projects and key sustainability projects and the allocation per executive may, subject to the Board's assessment, be reduced in the event of lower-than-planned performance on these research and development projects and key sustainability projects. Targets for non-financial performance related to sustainability and research and development projects may include achievement of certain milestones within set dates. Finally, the Board of Directors determines the expected average annual sales growth which shall be used as basis when finally calculating the size of the allocation at the end of the three-year vesting period given that the allocation can be reduced or increased by up to 30% depending on the average sales growth in the three-year vesting period.
Once the allocation per executive has been approved by the Board, the total cash amount is converted into Novo Nordisk B shares at market price. The market price is calculated as the average trading price for Novo Nordisk B shares on Nasdaq Copenhagen in the open trading window following the release of financial results for the year prior to the relevant performance year, i.e. in the open trading window following immediately after the Board’s approval of the programme.
The shares are allocated to the executives according to their base salary as per 1 April in the performance year.
The shares allocated per executive for a given year will be locked up for three years before they are transferred to individual executives. If an executive resigns during the vesting period, his or her allocated shares will be removed. At the end of the vesting period the allocation of shares will be reduced or increased by up to 30% depending on whether the actual average annual sales growth in the three-year vesting period is lower or higher compared to the expected average annual sales growth. The allocation cannot exceed 24 months’ fixed base salary plus pension contribution for the chief executive officer and 18 months’ fixed base salary plus pension contribution for the executive vice presidents.
In the vesting period the market value of the allocated shares per executive will change dependent upon the development in the Novo Nordisk B share price, aligning the interests of the executives with those of shareholders.
No dividends are paid on allocated shares in the vesting period and the allocated shares are administered as part of Novo Nordisk’s holding of treasury shares.
Novo Nordisk continuously covers its obligations under the long-term incentive programme through its holding of treasury shares.
Long-term incentives are subject to recovery or
"claw-back" by Novo Nordisk, provided the remuneration was
paid on the basis of data which proved to be manifestly misstated.
Claw-back in relation to the long-term incentives is possible up to 12
months after the release of the shares to the executives (i.e. four
years after allocation).
Pension contributions is up to 25 % of the fixed base salary including bonus.
Executives receive non-monetary benefits, such as company car, phones etc. Executives on international assignments may receive relocation benefits. Such benefits are approved by the Board by delegation of powers to the Remuneration Committee. The Remuneration Committee informs the Board of the process and outcome. In addition, executives may participate in programmes that are offered to all Novo Nordisk employees, such as employee share purchase programmes.
In the event of termination ─ whether by Novo Nordisk or by the individual ─ due to a merger, acquisition or takeover of Novo Nordisk, executives are, in addition to the notice period entitled to a severance payment of 24 months' fixed base salary plus pension contribution. In the event of termination by Novo Nordisk for other reasons, the severance payment is three months' fixed base salary plus pension contribution per year of employment as an executive and taking into account previous employment history. In no event will severance payment be less than 12 months’ or more than 24 months' fixed base salary plus pension contribution.
For each individual executive the total value of the remuneration relating to the notice period and of the severance pay does not exceed two years of remuneration, including all components of the remuneration. However, employment contracts entered into prior to 2008 allow for severance payments of up to 36 months’ fixed base salary plus pension contribution (i.e. a deviation from the 24 months above).
The severance payment may be reduced if the executive has or takes
up new employment after the expiry of the notice period. A reduction
has among other things to take into consideration the size of
severance payment and the remuneration related to the new employment.
Severance payment under contracts entered into before 2017 with
members of the Management Board may, however, not be reduced. The
Management Board consists of all members of Executive Management and
senior vice presidents.
The Board of Directors may when recruiting new executives who are not employed with Novo Nordisk at the time of employment grant a sign-on arrangement in the form of cash payment or share incentive programme.
To further align the interest of the shareholders and Executive Management the chief executive officer should hold Novo Nordisk B shares corresponding to twice the annual base salary plus pension contribution, and the executive vice presidents should hold shares corresponding to the annual base salary plus pension contribution. The Board of Directors may grant exemption to this requirement, e.g. in connection with a promotion to chief executive officer or executive vice president.
Policy for remuneration of board members and executives in Novo Nordisk A/S:
Information on the remuneration received by board members and executives in Novo Nordisk A/S:
Holding of shares
Information on the Novo Nordisk management’s holding of shares: